非小细胞肺癌靶向药物治疗争论热点  

Controversy on Target Therapy of Non-small Cell Lung Cancer

作　　者：秦宝丽[1] 椰慧楠[1] 宿濛[1] 

机构地区：[1]辽宁省肿瘤医院内二科,辽宁沈阳110042

出　　处：《医学与哲学（B）》2009年第6期7-10,共4页Medicine & Philosophy(B)

摘　　要：非小细胞肺癌作为全球和我国发病率最高、死亡人数最多的恶性肿瘤,其药物治疗始终是临床肿瘤学界高度关注的焦点之一。肿瘤的药物治疗模式从单纯以细胞毒药物杀伤肿瘤逐步向调节信号传导通路转变,分子靶向药物日益成为治疗肿瘤的重要武器。回顾肺癌靶向治疗的进展,诸多问题需要解决。In the whole globe and China, the incidence of non-small cell lung cancer （NSCLC） was the highest and death toll was the most among malignant tumors. Medicine treatment was always one of the utmost concerns in the clinical oncology field. The mode of medication was gradually changed from cytotoxic chemotherapy alone to regulation of signalling pathways. Target therapy was increasingly developed into important modality. In retrospect of advances in target therapy of NSCLC, many problems remained to answer.

关 键 词：非小细胞肺癌 靶向治疗 化疗 

分 类 号：R734.2[医药卫生—肿瘤]